Photofrin Approved for Early-Stage Lung Cancer
BUFFALO, NY-Photofrin (porfi-mer sodium), a photosensitizer used in photodynamic therapy (PDT), has received FDA approval for use in early-stage microinvasive lung cancer. The agent, manufactured by QLT Photo-Therapeutics, was approved in 1995 for palliative use in esophageal cancer.
BUFFALO, NYPhotofrin (porfi-mer sodium), a photosensitizer used in photodynamic therapy (PDT), has received FDA approval for use in early-stage microinvasive lung cancer. The agent, manufactured by QLT Photo-Therapeutics, was approved in 1995 for palliative use in esophageal cancer.
A press release from Roswell Park Cancer Institute notes that photodynamic therapy was developed and tested for use in a number of types of cancers by Thomas J. Dougherty, PhD, and his colleagues at Roswell Park.
In clinical trials sponsored by QLT PhotoTherapeutics, approximately 75% of patients had a complete response following treatment with Photofrin/PDT, and about half are cancer-free in up to 10 years of follow-up. Photofrin represents a potentially curative treatment for early-stage lung cancer patients who are not eligible for surgery or radiotherapy, the Roswell Park researchers said.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies
June 13th 2024"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."
